• γH2AX DNA Damage Detection Kit: Precision DNA Damage Biomark

  2026-07-09

  Leverage the γH2AX DNA Damage Detection Kit (Mouse mAb/Red) for rapid, high-sensitivity visualization of DNA double-strand breaks in genotoxicity, apoptosis, and DNA repair research. With robust immunofluorescence, streamlined workflows, and quantitative reliability, this APExBIO solution empowers next-generation translational and preclinical assays.

• Fluo-4 AM (SKU B8807): Reliable Calcium Imaging for Cell Ass

  2026-07-09

  This article delivers a scenario-driven, evidence-based exploration of Fluo-4 AM (SKU B8807) for intracellular calcium concentration measurement in cell viability, proliferation, and cytotoxicity assays. Drawing on real-world laboratory challenges and quantitative data, it demonstrates how this fluorescent calcium indicator from APExBIO provides robust, reproducible, and cost-effective solutions for biomedical researchers.

• Nanomedicine Restores Stromal Balance to Inhibit Pancreatic

  2026-07-08

  Fu et al. developed a multistage, acid-responsive nanomedicine that sequentially remodels the dense stroma of pancreatic ductal adenocarcinoma (PDAC), enabling deeper gemcitabine delivery and significant tumor regression in vivo. This work advances stromal reprogramming strategies, offering new directions for overcoming chemoresistance in pancreatic cancer.

• Y-27632: ROCK Inhibitor Protocols for Cytoskeletal Modulatio

  2026-07-08

  Y-27632 is a benchmark ROCK inhibitor enabling precise, reproducible modulation of cytoskeletal dynamics and cell stress fiber disruption in advanced cell biology, cancer, and epithelial regeneration studies. This guide delivers actionable protocols, troubleshooting tactics, and translational insights, drawing on the latest mucosal immunology and organoid research.

• Esflurbiprofen Blocks SERT-nNOS for Rapid Antidepressant Act

  2026-07-07

  This study identifies esflurbiprofen as a fast-onset antidepressant that works by disrupting the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) interaction in the dorsal raphe nucleus. The findings offer a promising alternative to conventional SSRIs, addressing the crucial need for rapid-acting therapies in major depressive disorder.

• Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea): Translatin

  2026-07-07

  Explore how Diuron, a potent photosynthesis inhibitor, offers breakthrough insights for acute kidney injury research. This article uniquely bridges advanced toxicological mechanisms with practical assay optimization, elevating Diuron's role in environmental and biomedical studies.

• Distinct Apoptosis Pathways in BMECs Induced by Candida krus

  2026-07-06

  This study reveals that the yeast and hypha phases of Candida krusei trigger apoptosis in bovine mammary epithelial cells via separate signaling routes, with the yeast form engaging the mitochondrial (intrinsic) pathway and the hypha form activating the death receptor (extrinsic) mechanism. These findings provide new mechanistic insights into fungal mastitis and highlight potential molecular targets for intervention.

• Bafilomycin A1 (SKU A8627): Precision V-ATPase Inhibitor Sol

  2026-07-06

  This in-depth, scenario-driven guide addresses common laboratory challenges in cell viability and lysosomal function research, focusing on the robust, reproducible performance of Bafilomycin A1 (SKU A8627). Drawing on quantitative data, peer-reviewed studies, and APExBIO’s validated supply, the article equips biomedical researchers and technicians with actionable workflows for optimal protocol design and reliable data interpretation.

• Gut-Brain Cholinergic Pathways in B. fragilis Antiseizure Ef

  2026-07-05

  Jia et al. uncover a gut-brain cholinergic signaling pathway by which Bacteroides fragilis suppresses seizures, revealing translational implications for pediatric refractory epilepsy. Their integrative study combines animal models, clinical data, and mechanistic probing to define a microbiota–neural circuit axis for seizure control.

• Formononetin Prevents Oxaliplatin Neurotoxicity Without Comp

  2026-07-04

  The reference study reveals that formononetin protects sensory neurons from oxaliplatin-induced peripheral neurotoxicity by activating the Nrf2/HO-1 antioxidant pathway, while preserving the chemotherapeutic efficacy of oxaliplatin and paclitaxel. These findings offer a significant advance in balancing neuroprotection with oncological outcomes in chemotherapy-induced peripheral neuropathy (CIPN) models.

• DiscoveryProbe Bioactive Compound Library Plus in High-Throu

  2026-07-03

  Leverage the DiscoveryProbe Bioactive Compound Library Plus to streamline ligand screening and pathway interrogation with 5,072 ready-to-use bioactive compounds. This guide details robust workflows, practical troubleshooting, and expert-driven assay optimization for protease inhibitor discovery and translational research.

• Deferoxamine (DeferoxamineB): Iron Chelation & Cancer Resear

  2026-07-03

  Deferoxamine (DeferoxamineB) is a validated iron chelator with proven roles in modulating iron metabolism, oxidative stress, and cell death pathways. It serves as a benchmark tool in cancer research for inducing apoptosis and autophagy. This article details its mechanistic, biochemical, and workflow parameters for reliable laboratory use.

• Nitrocefin: Chromogenic Cephalosporin Substrate in β-Lactama

  2026-07-02

  Nitrocefin enables rapid, visual detection of β-lactamase activity, streamlining antibiotic resistance profiling and inhibitor screening in both clinical and research settings. Leveraging cutting-edge findings from multidrug-resistant pathogens, this article delivers practical protocols, troubleshooting insights, and workflow enhancements that maximize assay sensitivity and reliability.

• Targeting FLT3-TAZ Signaling to Overcome Drug Resistance in

  2026-07-02

  Shin et al. (2023) identify FLT3 as a critical mediator of drug resistance in blast phase chronic myeloid leukemia (BP-CML), revealing a FLT3-JAK-STAT3-TAZ-TEAD-CD36 axis that operates independently of BCR::ABL1 mutations. Their findings suggest that repurposing FLT3 inhibitors, alone or in combination, can restore sensitivity to therapy in FLT3-positive BP-CML, opening new avenues for targeted intervention.

• Quantifying Drug-Induced Fractional Killing by High-Throughp

  2026-07-01

  The protocol by Inde et al. introduces a high-throughput microscopy method for quantifying fractional killing in cancer cell populations, enabling direct comparison of cell death kinetics across hundreds of experimental conditions. This advance allows researchers to dissect the heterogeneity of anti-cancer drug responses, with significant implications for optimizing apoptosis-inducing agents and understanding resistance mechanisms.

554 records 12/37 page Previous Next First page 上5页 1112131415 下5页 Last page